Literature DB >> 26198770

Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology.

Heike M Hermanns1.   

Abstract

Oncostatin M (OSM) and interleukin-31 (IL-31) are two cytokines belonging to the IL-6 family which share a common signaling receptor subunit, the OSM receptor beta (OSMRβ). Both of them are released by monocytes/macrophages, dendritic cells and T lymphocytes in inflammatory situations and upon binding to their respective receptor complexes they signal mainly via the JAK/STAT pathway. Besides sharing many biochemical properties, both display divergent physiological functions. This review summarizes aspects of cytokine transcription and biosynthesis, cytokine-receptor interactions, cross-species activities, signal transduction and physiology delineated from recent findings in genetic mouse models for both cytokines, OSM and IL-31.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; Inflammation; Interleukin-31; Oncostatin M; Signal transduction

Mesh:

Substances:

Year:  2015        PMID: 26198770     DOI: 10.1016/j.cytogfr.2015.07.006

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  77 in total

1.  Endothelial signaling by neutrophil-released oncostatin M enhances P-selectin-dependent inflammation and thrombosis.

Authors:  Hendra Setiadi; Tadayuki Yago; Zhenghui Liu; Rodger P McEver
Journal:  Blood Adv       Date:  2019-01-22

Review 2.  Interleukin-6 Family Cytokines.

Authors:  Stefan Rose-John
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-02-01       Impact factor: 10.005

3.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

4.  A role for oncostatin M in inflammatory bowel disease.

Authors:  Walter M Kim; Arthur Kaser; Richard S Blumberg
Journal:  Nat Med       Date:  2017-05-05       Impact factor: 53.440

5.  The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.

Authors:  Juan M Adrian-Segarra; Natalie Schindler; Praveen Gajawada; Holger Lörchner; Thomas Braun; Jochen Pöling
Journal:  J Biol Chem       Date:  2018-03-06       Impact factor: 5.157

6.  Oncostatin M and its role in fibrosis.

Authors:  Lukasz Stawski; Maria Trojanowska
Journal:  Connect Tissue Res       Date:  2018-07-30       Impact factor: 3.417

7.  Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.

Authors:  Emma C Walker; Rachelle W Johnson; Yifang Hu; Holly J Brennan; Ingrid J Poulton; Jian-Guo Zhang; Brendan J Jenkins; Gordon K Smyth; Nicos A Nicola; Natalie A Sims
Journal:  J Biol Chem       Date:  2016-08-18       Impact factor: 5.157

Review 8.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

9.  Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.

Authors:  Szu-Yuan Pu; Fei Xiao; Stanford Schor; Elena Bekerman; Fabio Zanini; Rina Barouch-Bentov; Claude M Nagamine; Shirit Einav
Journal:  Antiviral Res       Date:  2018-05-16       Impact factor: 5.970

Review 10.  IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

Authors:  Nese Unver; Florencia McAllister
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-18       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.